2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Monday, November 6, 2017

9:00AM-11:00AM: Abstract Number: 1232

The Perceived Impact of Recent-Onset Psoriatic Arthritis Is Different between Genders: A Spanish Multicenter Experience

Patient Outcomes, Preferences, and Attitudes Poster II

9:00AM-11:00AM: Abstract Number: 1496

The Performance of Different Classification Criteria in Patients with Primary Sjogren’s Syndrome and Analysis of Their Contribution for Definitive Diagnosis, When Either Criteria Used Alone or in Combination

Sjögren's Syndrome Poster II: Clinical Research

9:00AM-11:00AM: Abstract Number: 1045

The Potential Value of a Shared Decision-Making Intervention for Choices Regarding Triple Therapy in Rheumatoid Arthritis

Health Services Research Poster II: Osteoarthritis and Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1503

The Prevalence of Axial Spondyloarthritis in Israel

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster II

9:00AM-11:00AM: Abstract Number: 1005

The Prevalence of Patellofemoral Osteoarthritis in China: A Multi-Center Population-Based Cross-Sectional Study

ARHP Epidemiology and Public Health Poster

9:00AM-11:00AM: Abstract Number: 1432

The Prognostic Value of IgA Subtypes of Rheumatoid Factor and Anti-Citrullinated Protein Antibodies (ACPA) for Prediction of Therapeutic Responses to TNF Inhibitory Therapy in Patients with Rheumatoid Arthritis

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster II: Prognostic Factors, Imaging and Miscellaneous Reports

9:00AM-11:00AM: Abstract Number: 1461

The Relationship between Serum IL-37 and Disease Activity in Patients with Rheumatoid Arthritis: Post-Hoc Analysis of Planetra Study

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster II: Prognostic Factors, Imaging and Miscellaneous Reports

9:00AM-11:00AM: Abstract Number: 1352

The Relevance of Elevated CRP As an Inclusion Criterion in Clinical Trials in Patients with Rheumatoid Arthritis

Rheumatoid Arthritis – Clinical Aspects Poster II: Pathophysiology, Autoantibodies, and Disease Activity Measures

9:00AM-11:00AM: Abstract Number: 1014

The Rheumatic Disease Data Refinery: A Case Study in Integrative Genomics Reveals Complex IFN Signatures in Therapeutic Studies in SLE

Genetics, Genomics and Proteomics Poster II

9:00AM-11:00AM: Abstract Number: 1718

The Role and Function of Monocyte-Derived Fibroblast-like Cells in Multi-Organ Fibrosis in Systemic Sclerosis

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics Poster II

9:00AM-11:00AM: Abstract Number: 1377

The Serum Levels of Semaphorin 4D Are Associated with Disease Activity As Well As Radiographic Progression in Patients with Rheumatoid Arthritis

Rheumatoid Arthritis – Clinical Aspects Poster II: Pathophysiology, Autoantibodies, and Disease Activity Measures

9:00AM-11:00AM: Abstract Number: 1091

The Utility of Electronic Consultation in the Management of Gout at the Veterans Affairs Medical Center

Measures and Measurement of Healthcare Quality Poster I

9:00AM-11:00AM: Abstract Number: 1775

The Utility of the ACR/EULAR 2017 Provisional Classification Criteria for Granulomatosis with Polyangiitis in Korean Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

Vasculitis Poster II: ANCA-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 1783

The Value of a Combination of Serum Proteins to Identify Response to Induction Therapy Among Patients with ANCA-Associated Vasculitis

Vasculitis Poster II: ANCA-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 1418

The Value of Adalimumab Trough Levels and Clinical Assessments in Predicting Clinical Response in Patients with Established Rheumatoid Arthritis and an Inadequate Response to Methotrexate

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster II: Prognostic Factors, Imaging and Miscellaneous Reports

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].